Evidence map›Paper›PMID 40689605›Full record

SynthesisFuture cardiology2026

Angiotensin-neprilysin inhibition in acute decompensated heart failure: a meta-analysis of randomized controlled trials.

Hosam I Taha, Abdalhakim Shubietah, Bashar M Al Zoubi, Mohamed S Elgendy, Hazem Reyad Mansour, Anas Abdulkader, Abdelrahman M Ghazal, Noura Shamis, Mohamed Abuelazm, Mustafa Turkmani and 1 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hosam I TahaFaculty of Medicine, Tanta University, Tanta, Egypt.
Abdalhakim ShubietahDepartment of Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, USA.
Bashar M Al ZoubiFaculty of Medicine, The Hashemite University, Zarqa, Jordan.
Mohamed S ElgendyFaculty of Medicine, Tanta University, Tanta, Egypt.
Hazem Reyad MansourFaculty of Medicine, Tanta University, Tanta, Egypt.
Anas AbdulkaderCollege of Medicine, AlMaarefa University, Riyadh, Saudi Arabia.
Abdelrahman M GhazalFaculty of Medicine, Tanta University, Tanta, Egypt.
Noura ShamisFaculty of Medicine, Tanta University, Tanta, Egypt.
Mohamed AbuelazmFaculty of Medicine, Tanta University, Tanta, Egypt.
Mustafa TurkmaniFaculty of Medicine, Michigan State University, East Lansing, Michigan, USA.ORCID 0009-0001-4261-0638
Robert J MentzDivision of Cardiology and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAngiotensin receptor - neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety after stabilization of acute decompensation (ADHF) remain unclear. This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF.

methodsMeta-analysis of randomized controlled trials (RCTs) from PubMed, Scopus, WOS, Embase, and CENTRAL up to November 2024. Risk ratios (RR) and standardized mean differences (SMD) with 95% confidence intervals (CI) were used.

resultsThree RCTs (1,741 patients) were included. ARNI use after ADHF stabilization significantly reduced HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57-0.88;

conclusioninitiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk. PROTOCOL REGISTRATION: PROSPERO: CRD42024618027.

Indexed as

Angiotensin Receptor AntagonistsHeart FailureNeprilysinAcute DiseaseAngiotensin-Converting Enzyme InhibitorsHumansRandomized Controlled Trials as TopicAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsNeprilysinadvanceddecongestiverefractorysacubitrilvalsartanWorsening

Identifiers

PMID40689605
PMCPMC12773504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.